Literature DB >> 207782

Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma.

A M Arvin, R B Pollard, L E Rasmussen, T C Merigan.   

Abstract

Herpes zoster is a frequent complication of lymphoreticular malignancy. In this study two assays of in vitro cellular immune response to varicella-zoster virus (VZV) antigen, lymphocyte transformation and interferon production, were performed in normal subjects with recent and remote VZV infection. The responses of patients with lymphoma were measured before treatment and during long-term remission and then compared with those of normal subjects. Despite levels of antibody to VZV that were equivalent to those in normal subjects, 44% of the untreated lymphoma patients showed a lower transformation response to VZV antigen than the normal patients. Production of interferon in response to VZV antigen was absent in 32% of the untreated patients. In contrast, lymphocyte responses in untreated patients to herpes simplex virus antigen were within the range observed in a normal population. Interferon production by lymphocytes in response to cytomegalovirus antigen was also lower among untreated lymphoma patients than among normal patients, but lymphocyte transformation was not. Twenty-two percent of lymphoma patients in long-term remission continued to have diminished cellular immune responses to VZV antigen. Observations in these patient populations and in normal subjects with acute herpes zoster suggest that deficiencies in in vitro lymphocyte responses may correlate with increased susceptibility to clinical infection with VZV.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 207782     DOI: 10.1093/infdis/137.5.531

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

Review 1.  Preventing varicella-zoster disease.

Authors:  Sophie Hambleton; Anne A Gershon
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

2.  Specific in vitro antibody response to varicella zoster.

Authors:  R L Souhami; J Babbage; R E Callard
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

3.  Use of bone marrow fibroblasts to prepare targets for an HLA restricted-cytotoxicity assay system.

Authors:  R A Bowden; L McGavren; A R Hayward; M J Levin
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

4.  Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma.

Authors:  A M Arvin; R B Pollard; L E Rasmussen; T C Merigan
Journal:  J Clin Invest       Date:  1980-04       Impact factor: 14.808

5.  Arm Paralysis After Routine Childhood Vaccinations: Application of Advanced Molecular Methods to the Causality Assessment of an Adverse Event After Immunization.

Authors:  Jana Shaw; Neal A Halsey; Adriana Weinberg; D Scott Schmid; Kirsten St George; William C Weldon; Michael Jordan; Patrick W Bryant; Philip S LaRussa; Deborah Y Bradshaw; Theresa Harrington; Anne Gershon
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

Review 6.  Pathogenesis and current approaches to control of varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

7.  Effects of interferon and adenine arabinoside treatment of hepatitis B virus infection on cellular immune responses.

Authors:  B Hafkin; R B Pollard; M L Tiku; W S Robinson; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

8.  Cell-mediated and humoral immunity to herpesviruses during and after herpes zoster infections.

Authors:  O S Sørensen; S Haahr; A Møller-Larsen; K Wildenhoff
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

Review 9.  Varicella zoster vaccines and their implications for development of HSV vaccines.

Authors:  Anne A Gershon
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

10.  IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies.

Authors:  G N Malavige; L T Rohanachandra; L Jones; L Crack; M Perera; N Fernando; D Guruge; G S Ogg
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.